Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Rheumatology · Giant Cell Arteritis

Scans, Biopsies, and Differential Diagnosis

At a Glance

Disseminated visceral GCA is diagnosed by combining imaging—such as PET-CT, CTA, MRA, or ultrasound—with clinical information and occasional tissue findings. A negative temporal artery biopsy may not rule it out because inflammation can be limited to internal arteries.

Because disseminated visceral GCA involves arteries deep inside the body, it cannot be diagnosed with a simple physical exam or a single blood test. Doctors must act like detectives, combining your symptoms, advanced imaging, and sometimes tissue samples to create a “map” of where the immune system is attacking [1][2].

The Role of Biopsy

In standard GCA, a temporal artery biopsy (a small procedure near the temple) is a highly valued tool. However, in the disseminated visceral form, this biopsy is often negative because the inflammation is focused on internal organs rather than the head [3][4].

A negative temporal artery biopsy does not rule out visceral GCA. False negatives can also happen if the inflammation “skips” areas, if the sample is too short, or if you were on glucocorticoids for a while. If your doctor suspects this rare pattern, they will look for evidence elsewhere, often through advanced scans or samples taken during other clinically necessary surgeries (such as an aneurysm repair) [1][5]. Invasive internal biopsies are not routinely performed just to prove the diagnosis.

Advanced Imaging: Seeing the Inflammation

Since doctors cannot easily biopsy your internal organs, they use detailed scans to see the inflammation [6][2]. There is no single “perfect” scan; each modality answers a different question.

  • FDG-PET/CT: This scan uses a small amount of radioactive sugar that “lights up” where cells are metabolically active. In visceral GCA, the walls of the aorta and other internal arteries may show intense “uptake”—often graded against the activity in your liver [7][8]. Be aware that uptake isn’t perfectly specific to vasculitis; atherosclerosis or infections can also cause it.
  • CTA and MRA: These scans provide a detailed look at the structure of your arteries. Doctors look for concentric wall thickening (the “pipe” wall getting thicker all the way around) and structural damage like stenosis (narrowing) or aneurysms (bulging) [9][10].
  • Ultrasound: Specialized ultrasound can check for a “halo” of inflammation around the arteries, including the axillary arteries (near the armpits), which are frequently involved in large-vessel GCA [6][11].

What the Pathologist Looks For

If a piece of an artery is removed during a necessary surgery, a pathologist examines it under a microscope. They are looking for specific biological “fingerprints” of GCA [12][13]:

  1. Granulomatous Inflammation: A specific pattern of immune cells clustered together.
  2. Multinucleated Giant Cells: Large, fused immune cells that are a hallmark of this disease, though they aren’t always present [14][15].
  3. Elastic Lamina Destruction: The disease specifically targets and breaks down the flexible “internal elastic” layer of the artery wall [12][13].
  4. Intimal Hyperplasia: The innermost lining of the artery grows too thick, which can eventually block blood flow [16][17].

Ruling Out Other Conditions

Visceral GCA can look like other rare diseases. Your care team must rule these out to ensure you get the right treatment:

  • Takayasu Arteritis: Very similar to GCA but typically affects people under age 50 [2][18].
  • Polyarteritis Nodosa (PAN): Affects medium-sized arteries but usually causes “beading” or small knots on the vessels rather than the smooth, long thickening seen in GCA [19].
  • IgG4-Related Disease: A condition where the body produces too many IgG4-positive plasma cells, which can cause artery inflammation that looks similar on a scan but requires different pathology to identify [20].
  • Infections: Certain infections can cause “mycotic” (infected) aneurysms that mimic vasculitis [20][21].

Your Report Completeness Checklist

When reviewing your imaging or pathology reports, look for these specific data points. If they are missing, it is a good topic to discuss with your doctor:

  • [ ] Vascular Territories: Does the report mention the aorta, mesenteric (intestinal), or renal (kidney) arteries specifically? [22]
  • [ ] Uptake Level (PET-CT): Does the report compare the artery “brightness” to the liver or the blood pool? [8]
  • [ ] Wall Characteristics: Are the artery walls described as “thickened,” “enhanced,” or “concentric”? [9]
  • [ ] Biopsy Details: If a biopsy was done, does it mention “giant cells” or “internal elastic lamina fragmentation”? [12]
  • [ ] Steroid Timing: Does the report note if you were already on high-dose steroids (which can make the scans look “cleaner” than they actually are)? [7][23]

Common questions in this guide

Can a negative temporal artery biopsy rule out visceral GCA?
No. In disseminated visceral GCA, inflammation may be limited to arteries inside the body, so a sample from the temple can be negative. Sampling gaps, a short specimen, or prior glucocorticoid treatment can also cause a false-negative result.
Which scans are used to look for internal artery inflammation in GCA?
Doctors may use FDG-PET/CT, CTA, MRA, and specialized ultrasound. PET-CT can show metabolically active artery walls, CTA and MRA show wall thickening or structural damage, and ultrasound can show a halo around affected arteries. No single scan answers every diagnostic question.
Does increased FDG uptake on a PET-CT prove that I have visceral GCA?
No. Increased uptake shows metabolic activity in the artery wall, but atherosclerosis and infection can also cause uptake. Doctors interpret the finding with the overall clinical picture and other imaging results.
What might an artery biopsy show in giant cell arteritis?
Pathologists may look for granulomatous inflammation, multinucleated giant cells, destruction of the internal elastic layer, and thickening of the inner artery lining. Giant cells are a hallmark but may not be present in every tissue sample.
How do doctors tell visceral GCA apart from Takayasu arteritis and other mimics?
Age and vessel appearance help distinguish these conditions: an age over 50 supports GCA over Takayasu arteritis, which typically affects people under 50. Beaded arteries can suggest polyarteritis nodosa, special tissue findings can support IgG4-related disease, and infection can cause infected aneurysms that mimic vasculitis.
Why should I tell my doctor exactly when I took steroids before imaging?
Glucocorticoids can reduce visible inflammation, making a scan look cleaner than it otherwise might. Sharing the dates you started and stopped them helps the care team interpret the results in context.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on disseminated visceral giant cell angiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.If my temporal artery biopsy was negative, why do you still suspect 'disseminated visceral' GCA?
  2. 2.Does my imaging report show 'concentric thickening' or 'increased FDG uptake' in my internal arteries?
  3. 3.How does the appearance of my arteries on the scan help you rule out other conditions like Takayasu's or IgG4-related disease?
  4. 4.Was my PET-CT scan compared to my liver's activity level to confirm the inflammation is active?
  5. 5.If I have had a biopsy of an internal organ or artery, did the pathologist find 'multinucleated giant cells' or 'fragmentation of the internal elastic lamina'?

References

References (23)
  1. 1

    Imaging Tests in the Early Diagnosis of Giant Cell Arteritis.

    Prieto-Peña D, Castañeda S, Martínez-Rodríguez I, et al.

    Journal of clinical medicine 2021; (10(16)) doi:10.3390/jcm10163704.

    PMID: 34442002
  2. 2

    Large vessel giant cell arteritis.

    van der Geest KSM, Sandovici M, Bley TA, et al.

    The Lancet. Rheumatology 2024; (6(6)):e397-e408 doi:10.1016/S2665-9913(23)00300-4.

    PMID: 38574745
  3. 3

    Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, non-interventional, cohort study.

    Chrysidis S, Døhn UM, Terslev L, et al.

    The Lancet. Rheumatology 2021; (3(12)):e865-e873 doi:10.1016/S2665-9913(21)00246-0.

    PMID: 38287632
  4. 4

    Extracranial giant cell arteritis: A narrative review.

    Lensen KD, Voskuyl AE, Comans EF, et al.

    The Netherlands journal of medicine 2016; (74(5)):182-92.

    PMID: 27323671
  5. 5

    Posterior ischemic optic neuropathy as the main manifestation of giant cell arteritis: a case-based literature review.

    Barankiewicz-Tyc N, Wąsik N, Majewski P, et al.

    Reumatologia 2026; (64(1)):65-71 doi:10.5114/reum/207774.

    PMID: 41909066
  6. 6

    EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.

    Dejaco C, Ramiro S, Bond M, et al.

    Annals of the rheumatic diseases 2024; (83(6)):741-751 doi:10.1136/ard-2023-224543.

    PMID: 37550004
  7. 7

    Digital [18F]FDG PET/CT as first-line diagnostic modality for cranial giant cell arteritis.

    Abikhzer G, Roy A, Samson M, et al.

    European journal of nuclear medicine and molecular imaging 2026; doi:10.1007/s00259-026-08131-7.

    PMID: 42625054
  8. 8

    Large-vessel vasculitis: interobserver agreement and diagnostic accuracy of 18F-FDG-PET/CT.

    Lensen KD, Comans EF, Voskuyl AE, et al.

    BioMed research international 2015; (2015()):914692 doi:10.1155/2015/914692.

    PMID: 25695092
  9. 9

    Diagnostic Approaches for Large Vessel Vasculitides.

    Betrains A, Blockmans D

    Open access rheumatology : research and reviews 2021; (13()):153-165 doi:10.2147/OARRR.S282605.

    PMID: 34113183
  10. 10

    Imaging in large-vessel vasculitis.

    Schmidt WA, Nielsen BD

    Best practice & research. Clinical rheumatology 2020; (34(6)):101589 doi:10.1016/j.berh.2020.101589.

    PMID: 32948434
  11. 11

    Diagnostic yield of combined cranial and large vessel PET/CT, ultrasound and MRI in giant cell arteritis: A systematic review and meta-analysis.

    Moreel L, Betrains A, Doumen M, et al.

    Autoimmunity reviews 2023; (22(7)):103355 doi:10.1016/j.autrev.2023.103355.

    PMID: 37146926
  12. 12

    Giant cell arteritis without cranial manifestations caused mesenteric involvement: a case report.

    Miyake Y, Morimoto Y, Taniguchi M, et al.

    Surgical case reports 2019; (5(1)):119 doi:10.1186/s40792-019-0678-6.

    PMID: 31342194
  13. 13

    Giant cell arteritis in a patient with aortic dissection: a case report.

    Obikane H, Fujiyoshi T, Takahashi S, et al.

    Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2020; (46()):107206 doi:10.1016/j.carpath.2020.107206.

    PMID: 32062108
  14. 14

    A unique autopsy case of ascending aortic dissection caused by giant cell arteritis without drug therapy.

    Takase Y, Murakami Y, Nishi J, et al.

    Pathology international 2019; (69(10)):614-618 doi:10.1111/pin.12845.

    PMID: 31402553
  15. 15

    Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis.

    Jiemy WF, van Sleen Y, van der Geest KS, et al.

    Clinical & translational immunology 2020; (9(9)):e1164 doi:10.1002/cti2.1164.

    PMID: 32884747
  16. 16

    Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis.

    Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, et al.

    Annals of the rheumatic diseases 2017; (76(9)):1624-1634 doi:10.1136/annrheumdis-2016-210792.

    PMID: 28606962
  17. 17

    Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss.

    van der Geest KSM, Wolfe K, Borg F, et al.

    Rheumatology (Oxford, England) 2021; (60(9)):4361-4366 doi:10.1093/rheumatology/keaa806.

    PMID: 33355340
  18. 18

    [Eye involvement in large vesssel vasculitis (giant cell arteritis and Takayasu's arteritis)].

    Neß T, Schmidt W

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2019; (116(9)):899-914 doi:10.1007/s00347-019-00959-9.

    PMID: 31463637
  19. 19

    Imaging features of 18F-FDG PET/CT in different types of systemic vasculitis.

    Chen Z, Zhao Y, Wang Q, et al.

    Clinical rheumatology 2022; (41(5)):1499-1509 doi:10.1007/s10067-021-06039-1.

    PMID: 35088208
  20. 20

    Large Vessel Vasculitis Revisited: Mechanistic Insights and Advances in Diagnosis and Management.

    Peverelli M, Bond T, Wall C, et al.

    Journal of the American Heart Association 2026; (15(15)):e047156 doi:10.1161/JAHA.125.047156.

    PMID: 42517443
  21. 21

    Clinical characterization of aortitis and periaortitis: study of 134 patients from a single university hospital.

    Secada-Gómez C, Loricera J, Martín-Gutiérrez A, et al.

    Internal and emergency medicine 2025; (20(4)):1045-1057 doi:10.1007/s11739-025-03908-4.

    PMID: 40038164
  22. 22

    Comparative analysis of arterial involvement in predominant cranial and isolated extracranial phenotypes of giant cell arteritis using 18F-FDG PET-CT.

    Narvaez J, Vidal-Montal P, Sánchez-Rodríguez I, et al.

    Arthritis research & therapy 2024; (26(1)):230 doi:10.1186/s13075-024-03464-w.

    PMID: 39732686
  23. 23

    Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy.

    Nielsen BD, Gormsen LC, Hansen IT, et al.

    European journal of nuclear medicine and molecular imaging 2018; (45(7)):1119-1128 doi:10.1007/s00259-018-4021-4.

    PMID: 29671039

This page explains scans, biopsies, and differential diagnosis in disseminated visceral GCA for informational purposes only and does not constitute medical advice. Your care team must interpret your individual imaging and pathology results.